ОЦЕНКА ЭФФЕКТИВНОСТИ ЛЕЧЕНИЯ СИНДРОМА ГИЙЕНА-БАРРЕ  В УСЛОВИЯХ РЕАНИМАЦИИ

A.K. Moldotashova; E.A. Chernomazova; V.V. Babaev; Yu.S. Kabylov

doi:10.54890/.v2i2.539

A.K. Moldotashova E.A. Chernomazova V.V. Babaev Yu.S. Kabylov

DOI:

https://doi.org/10.54890/.v2i2.539

Abstract

Resume: This article presents the data of the pathogenetic approach to the treatment of Guillain – Barre syndrome in conditions of intensive care department. The clinical effects of plasmapharesis and immunoglobulin G on the example of clinical observations of patients with this neurological disorders passed through the intensive care unit are given.

Keywords:

Guillain – Barre syndrome, polyradiculoneuropathy, treatment, plasmapharesis, immunoglobulin G.

Author Biographies

A.K. Moldotashova, Kyrgyz State Medical Academy named after I.K. Akhunbaev

Department of General Surgery with the course of Anesthesiology and Intensive Care named after I.K. Akhunbaev

E.A. Chernomazova, Kyrgyz State Medical Academy named after I.K. Akhunbaev

Department of General Surgery with the course of Anesthesiology and Intensive Care named after I.K. Akhunbaev

V.V. Babaev, Kyrgyz State Medical Academy named after I.K. Akhunbaev

Department of General Surgery with the course of Anesthesiology and Intensive Care named after I.K. Akhunbaev

Yu.S. Kabylov, Kyrgyz State Medical Academy named after I.K. Akhunbaev

Department of General Surgery with the course of Anesthesiology and Intensive Care named after I.K.Akhunbaev

References

1. Пирадов М.А., Супонева Н.А. Синдром Гийена-Барре: диагностика и лечение. М.: МЕДпресс-информ. 2011. 208 с.

2. Mc Grogan A., Madle G.C., Seaman H.E., et al. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neiroepidemiology. 2009; 32 (2). С.150 – 163.

3. Burns T.M. Guillain-Barré syndrome. Semin. Neurol. 2008. №28 (2). С. 152-167.

4. Супонева Н.А., Мочалова Е.Г., Гришина Д.А. и др. Особенности течения СГБ в России: анализ 186 случаев. Нервно-мышечные болезни. 2014.С.37 – 46.

5. Супонева Н.А., Пирадов М.А., Гришина Д.А. и др. Эффективность патогенетической терапии при синдроме Гийена-Барре. Эффективная фармакотерапия. 2014. №58.C.12 – 23.

6. Hughes R.A., Cornblath D.R. Guillain-Barré syndrome. Lancet. 2005. №366.C. 1653 – 1666.

7. Levin K.H. Variants and mimics of GuillainBarré syndrome. Neurologist. 2004 №10. C. 61 – 74.

8. Willison H.J. Ganeglioside complexes as targets for antibodies in Miller Fisher syndrome. J. Neurol. Neurosurg. Psychiatry. 2006. №77 (9). C. 1002 – 1003.

9. Супонева Н.А. Клиническая и диагностическая роль аутоантител к гликозидам периферических нервов: обзор литературы и собственные данные. Нервно-мышечные болезни. 2013. №1.C. 26 – 35.

10. Susuki K., Rasband M.N., Tohyama K. et al. Anti-GM1 antibodies cause cjmplement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J. Neurosci. 2007. №27 (15).P. 3956 – 3967.

11. Yuki N. Guillain-Barré syndrome and anti-gangli-oside antibodies a clinician-scientist's jorney. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2012. №88 (7)P. 299 – 326.

12. Balogun R.A., Kaplan A., Ward D.M. et al. Clinical application of therapeutic apheresis. J. Clin. Apher-esis. 2010. №25. P. 250 – 264.

13. Szczepiorkowski Z.M., Winters J.L., Bandarenko N. et. al. Guidelines on the Use of Therapeutics Apheresis in Clinical Practice-Evidence-Based Approach from the Apheresis Applications Committee of the American Society for Apheresis. J. Clin. Apheresis. 2010.№25. P. 83 – 177.

14. Donofrio P.D. Immunotherapy of idiopathic inflam-matory neuropathies.Muscle Nerve. 2003. №28 (3). P.273 – 292.

15. Dada M.A., Kaplan A.A. Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over IVIg in patients with axonal involvement. Ther. Apher. Dial. 2004.№8.P. 409 – 412.